中国神经再生研究(英文版) ›› 2026, Vol. 21 ›› Issue (7): 2501-2525.doi: 10.4103/NRR.NRR-D-25-00364

• 综述:脑损伤修复保护与再生 •    下一篇

中性粒细胞外陷阱在脑卒中病理学中的演变及作用机制

  

  • 出版日期:2026-07-15 发布日期:2025-10-16
  • 基金资助:
    山东省自然科学基金(ZR2022MH124)和泰安市科技发展基金(2023NS155,2023NS164)。

Evolution of neutrophil extracellular traps in the pathology of stroke

Wenjing Ning1 , Qian Wang2, *, Yuzhen Xu1, *   

  1. 1 Department of Rehabilitation, The Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong Province, China;  2 Department of Central Laboratory, The Affiliated Taian City Central Hospital of Qingdao University, Taian, Shandong Province, China
  • Online:2026-07-15 Published:2025-10-16
  • Contact: Qian Wang, PhD, qianqianwangxi@163.com; Yuzhen Xu, PhD, xuyuzhen@sdfmu.edu.cn.
  • Supported by:
    The work was supported by the Natural Science Foundation of Shandong Province, No. ZR2022MH124 (to YX); Taian Science and Technology Development Fund, Nos. 2023NS155 (to QW), 2023NS164 (to WN).

摘要:

脑卒中是全球主要致死和致残原因之一,其发病机制复杂,涉及血栓形成、缺血再灌注损伤、炎症反应及血脑屏障破坏等多重病理过程。近年来,研究发现中性粒细胞外陷阱中性粒细胞外陷阱参与机体的抗感染防御,并在脑卒中中发挥重要作用。研究表明,中性粒细胞外陷阱可促进缺血性脑卒中中的血栓扩张和神经炎症,并在出血性脑卒中中通过调节局部炎症和影响血肿清除,参与疾病进展和恢复过程。此综述的目的是总结中性粒细胞外陷阱在脑卒中病理中的演变及作用机制。活性氧在脑梗死后6–24 h驱动中性粒细胞外陷阱形成;在脑梗死后24–48 h,其加剧血管损伤和血栓形成;在脑梗死后48–72 h,其加重神经损伤;脑梗死72 h后,中性粒细胞外陷阱参与血脑屏障破坏及炎症反应的维持。在脑卒中发展过程中,中性粒细胞外陷阱在脑梗死后参与多种病理机制,它们诱导血管内皮损伤,加剧血管渗漏和水肿,损伤神经元,诱导凋亡,促进血栓形成,参与再灌注损伤,并破坏血脑屏障。在出血性脑卒中中,中性粒细胞外陷阱与血肿清除、早期脑损伤和延迟性脑缺血密切相关,可作为评估疾病进展和疗效的生物标志物。在脑卒中急性期,中性粒细胞外陷阱主要促进损伤,而在慢性期,它们主要促进修复。作为脑卒中的重要生物标志物,中性粒细胞外陷阱与脑卒中严重程度密切相关。此外,中性粒细胞外陷阱在动脉粥样硬化和颅内静脉血栓形成中也发挥重要作用。目前,有研究已经证实脱氧核糖核酸酶是降解中性粒细胞外陷阱的关键药物,并显示出显著的治疗潜力。肽基精氨酸脱氨酶4抑制剂、高移动性组盒1拮抗剂通过各自独特的机制有效抑制中性粒细胞外陷阱的形成,针对中性粒细胞外陷阱的多靶点干预策略展现出广阔的临床应用前景。总之,中性粒细胞外陷阱与抗凝剂和溶栓药物具有协同作用,针对中性粒细胞外陷阱的干预措施会影响抗凝和溶栓治疗的疗效,这为开发脑卒中的新抗凝和溶栓策略以及改善患者的临床预后提供了理论依据。

https://orcid.org/0000-0002-5031-0686 (Qian Wang); https://orcid.org/0000-0002-1289-3438 (Yuzhen Xu)

关键词: 动脉粥样硬化, 出血性脑卒中, 脑出血, 脑血管疾病, 缺血性脑卒中, 中性粒细胞外陷阱, 神经系统损伤, 神经炎症性疾病, 再灌注损伤, 脑卒中, 蛛网膜下腔出血, 静脉窦血栓形成, 颅内, 血栓形成, 治疗, 血管内皮

Abstract: Stroke is a major cause of death and disability worldwide, and its pathogenesis is complex, involving multiple pathological processes, such as thrombosis, ischemia-reperfusion injury, inflammatory response, and blood–brain barrier disruption. In recent years, neutrophil extracellular traps have been found to be involved in the body’s anti-infection defense and to play an important role in stroke. Studies have shown that neutrophil extracellular traps promote thrombus expansion and neuroinflammation in ischemic stroke, and they may be involved in disease progression and recovery in hemorrhagic stroke by modulating local inflammation and influencing hematoma clearance. This review systematically summarizes the evolution and mechanism of action of neutrophil extracellular traps in stroke pathology. Reactive oxygen species drive the formation of neutrophil extracellular traps 6–24 hours after cerebral infarction. At 24–48 hours, they exacerbate vascular injury and thrombosis, at 48–72 hours, they aggravate neurological injury, and after 72 hours, neutrophil extracellular traps are involved in the disruption of the blood–brain barrier and the maintenance of the inflammatory response. During stroke development, neutrophil extracellular traps are involved in multiple pathological mechanisms after cerebral infarction. They induce vascular endothelial damage, exacerbating vascular leakage and edema, injuring neurons, inducing apoptosis, promoting thrombosis, participating in reperfusion injury, and damaging the blood–brain barrier. In hemorrhagic stroke, neutrophil extracellular traps are closely associated with hematoma clearance, early brain injury, and delayed cerebral ischemia, and can be used as a biomarker to assess disease progression and efficacy. In the acute phase of stroke, neutrophil extracellular traps mainly promote injury, and in the chronic phase, they mainly promote repair. Neutrophil extracellular traps, as an important biomarker of stroke, are closely correlated with stroke severity. Additionally, neutrophil extracellular traps play an important role in atherosclerosis and intracranial venous thrombosis. Current research has confirmed that deoxyribonuclease is a key drug for degrading neutrophil extracellular traps and has shown significant therapeutic potential. Peptidyl arginine deiminase 4 inhibitors and high mobility group box 1 antagonists effectively inhibit the formation of neutrophil extracellular traps through their own unique mechanisms. Multi-targeted intervention strategies for neutrophil extracellular traps have shown broad clinical application prospects. Neutrophil extracellular traps exhibit synergistic effects with anticoagulants and thrombolytic drugs, and interventions targeting neutrophil extracellular traps can influence the efficacy of anticoagulation and thrombolytic therapy. These findings provide a theoretical basis for developing new anticoagulation and thrombolysis strategies for stroke and improving clinical outcomes for patients.

Key words: atherosclerosis, cerebral hemorrhage, cerebrovascular disorders, intracranial, sinus thrombosis, stroke, subarachnoid hemorrhage, therapeutic, thrombosis, vascular endothelium